There is an increasingly important enabling technology in gene therapy and nucleic acid delivery: the use of DNA Gyrase to generate highly supercoiled plasmid DNA, a topology that is strongly correlated with improved delivery efficiency and functional expression and enhanced efficiency in gene therapy.

DNA gyrase, a bacterial Type II topoisomerase, is uniquely capable of introducing negative supercoils into closed circular DNA in an ATP-dependent manner, thereby compacting DNA and modulating its topology (Wikipedia). This structural state is not merely a biochemical curiosity—it has direct and measurable implications for gene delivery performance.

A growing body of literature supports the importance of supercoiled DNA in therapeutic contexts:

• Supercoiled plasmid DNA demonstrates significantly higher transfection efficiency compared to relaxed or linear DNA forms, with relaxed DNA achieving only ~75% of the efficiency of supercoiled constructs.
• Recent studies show that engineered supercoiled DNA constructs yield markedly improved cellular uptake and expression in mammalian systems, including HeLa and muscle cell models (OUP Academic).
• Supercoiled DNA is also more resistant to physical stress (e.g., shear, aerosolization), a key advantage for in vivo delivery platforms and formulation workflows (Nature).
• Process engineering strategies that enhance gyrase-mediated supercoiling have been explicitly proposed to improve plasmid quality for gene therapy applications (Analytical Science Journals).

Mechanistically, supercoiling increases DNA compactness and reduces entanglement, facilitating cellular uptake, nuclear trafficking, and transcriptional accessibility—all critical parameters in both viral and non-viral delivery systems.

At TopoGEN, we have seen firsthand the growing demand for high-quality DNA gyrase in this application space. Leading organizations—including major players in mRNA and nucleic acid therapeutics such as Moderna—have incorporated gyrase into their workflows to optimize plasmid topology for downstream delivery and expression.

Why TopoGEN DNA Gyrase

• Industry-leading purity and activity for consistent supercoiling performance
• Validated in both research and translational workflows
• Scalable production—we can accommodate large-volume orders without delay
• Batch-to-batch consistency with performance assurance and technical support
• Product in stock and available immediately

In addition, TopoGEN maintains an established global distribution network, including dedicated partners across Asia, ensuring efficient logistics, regulatory handling, and rapid delivery to your laboratory or production facility.

We stand behind our enzymes and are confident in their ability to deliver reproducible, high-performance outcomes in demanding gene therapy and nucleic acid delivery applications.

If you are exploring strategies to enhance plasmid quality, delivery efficiency, or expression performance, we would welcome the opportunity to discuss how DNA Gyrase can be integrated into your workflow.  Contact us today!